Citigroup
NMRA icon

Citigroup’s Neumora Therapeutics NMRA Stock Holding History

Citigroup’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-99,800
Closed -$1.06M – 5828
2024
Q4 		$1.06M Buy
+99,800
New +$1.2M ﹤0.01% 3321

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's NMRA Position: Q2 2026 in Review

Citigroup increased its Neumora Therapeutics (NMRA) stake by 7.6% in Q2 2026, buying an estimated $7.06K and bringing the position to 52,503 shares worth $89.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4747.

Citigroup first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.14M in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Citigroup held 52,503 shares of Neumora Therapeutics worth $89.3K as of Q2 2026.
  • Citigroup bought 3,710 Neumora Therapeutics shares in Q2 2026, an estimated $7.06K.
  • Neumora Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4747 holding.
  • Citigroup first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Citigroup's Neumora Therapeutics position peaked at $1.14M in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.